Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 11/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.41 |
| ▸ | ALKBH3 | Q96Q83 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | ALPL | P05186 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | ALPI | P09923 | 1/20 | 0.41 |
| ▸ | ALPG | P10696 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CASP1 | P29466 | 1/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3501351 | 0.80 | KDM4E (0.59) | AURKAKDM4EALKBH3MEN1TP53 | |
| SCHEMBL3503054 | 0.79 | KDM4E (0.52) | AURKAKDM4EALKBH3MEN1TP53 | |
| SCHEMBL3500883 | 0.78 | AURKA (0.64) | AURKAKDM4EALKBH3MEN1TP53 | |
| SCHEMBL4305932 | 0.78 | AURKA (0.52) | AURKAKDM4EALKBH3MEN1TP53 | |
| SCHEMBL1054292 | 0.77 | AURKA (0.64) | AURKAKDM4EALKBH3MEN1TP53 | |
| SCHEMBL3502168 | 0.77 | KDM4E (0.47) | AURKAKDM4EALKBH3MEN1TP53 | |
| SCHEMBL3502120 | 0.74 | AURKA (0.53) | AURKAKDM4EALKBH3MEN1TP53 | |
| SCHEMBL1052301 | 0.72 | AURKA (0.69) | AURKAKDM4EALKBH3MEN1TP53 | |
| SCHEMBL1054586 | 0.72 | AURKA (0.53) | AURKAKDM4EALKBH3MEN1TP53 | |
| SCHEMBL3501837 | 0.71 | AURKA (0.50) | AURKAKDM4EALKBH3MEN1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7825132-B2 | Inhibition of FGFR3 and treatment of multiple myeloma | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2010-11-02 | — | — | US | disclosed |
| US-20050261307-A1 | Inhibition of FGFR3 and treatment of multiple myeloma | CHIRON CORPORATION | 2005-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261307-A1 | Inhibition of FGFR3 and treatment of multiple myeloma | FGFR3, FGFR1, FGFR2 | AURKA 936/4885KDM4E 3240/4885ALKBH3 3719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.